FDA new drug approvals hit a 16-year high with 39 drugs approved in 2012; the highest number since 1996 when 53 drugs were approved. Of those, 18 or slightly less than half, were biologics up from 12 in 2011 but still surprisingly low when you consider an industry report citing that nearly 40 percent of … Continue reading “The Holy Grail of Drug Development: Small Molecules with the Power of Biologics”
Author: Nick Terrett
Nick Terrett joined Ensemble Therapeutics as the Chief Science Officer in May of 2006. In his role as CSO, Nick heads up our drug discovery program investigating the rapid synthesis of macrocycles using DNA-Programmed Chemistry, as drug candidates for disease relevant protein-protein and protease targets.
After working as a medicinal chemist for Glaxo, Nick joined Pfizer in Sandwich, England in 1984. He worked initially in cardiovascular disease, and is an inventor on patents for the neutral endopeptidase inhibitor candoxatrilat. Later he led the chemistry team on cGMP PDE inhibitors for angina and erectile dysfunction, and is an inventor on patents for Viagra®. Subsequently, Nick established Pfizer’s combinatorial chemistry group and authored several related papers and a textbook. He also managed the high throughput screening group and materials management, and played a key role in the global integration of the Pfizer, Warner-Lambert and Pharmacia compound collections. In 2003 Nick moved to the Pfizer Research Technology Center in Cambridge, Massachusetts, to lead the Chemical Sciences group investigating new targets for drug discovery and new chemistry technologies.